Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Provided By GlobeNewswire
Last update: Nov 13, 2024
Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25
Read more at globenewswire.com
